(secondQuint)AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma.

 OBJECTIVES: I.

 To assess the efficacy of AZD0530, in terms of disease control rate (i.

e.

, response rate and stable disease rate), in patients with recurrent locally advanced or metastatic soft tissue sarcoma.

 II.

 To assess the toxicity, time to progression, and response duration of AZD0530 in these patients.

 OUTLINE: This is a multicenter study.

 Patients receive oral AZD0530 once daily in the absence of disease progression or unacceptable toxicity.

 After completion of study therapy, patients are followed every 8 weeks.

.

 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma@highlight

This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.

 AZD0530 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

